A novel circulating tumor cell blood test for early detection of colorectal, prostate, and breast cancers: Results from 709 samples.

e13549Background: Early detection is key to reducing cancer deaths. Despite available screening options for many cancers, patients are still diagnosed in advanced stages. A sensitive, affordable blood test could improve testing compliance, and detect cancer at earlier, more treatable stages. Here we present results from prospective, multi-center, IRB-approved studies for colorectal, prostate and breast cancer. Methods: 2 to 4 mL blood were processed through the CMx test platform which includes biomimetic chip, proprietary EpCAM antibody and an air foam release mechanism to increase sensitivity. Released CTCs were confirmed with tissue-specific antibodies CK20, PSMA and mammaglobin. The diagnosis and staging of cancers was confirmed by biopsy. For colorectal and prostate cancer, a scoring system was developed based on an algorithm that incorporated CTCs and age. For breast cancer, a preliminary scoring is being evaluated. Results: In colorectal cancer, 620 subjects were evaluated and the test had a sensiti...